This is what could happen to a patient with asthma, taking metoprolol.
In general, beta-adrenergic receptor blocking agents (i.e., beta-blockers) should not be used in patients with bronchospastic diseases. Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors. If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless. Cardioselectivity is not absolute and can be lost with larger doses.
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 10 Apr 2013 • 1 answer
Posted 1 Aug 2013 • 1 answer
Posted 1 Apr 2014 • 1 answer
Posted 25 Aug 2016 • 1 answer
Posted 29 Dec 2017 • 1 answer